- Title
- Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up
- Creators
- A. Oliver Sartor - Tulane Cancer Center, New Orleans, LADaniel Heinrich - Akershus University HospitalNeil Mariados - Associated Medical Professionals of New York, PLLC, Syracuse, NYMaría José Méndez-Vidal - Hospital Universitario Reina SofíaDaniel Keizman - Meir Medical CenterCamilla Thellenberg Karlsson - Cancer Center Norrlands University, Umeå, SwedenAvivit Pe'er - Rambam Medical Center, Haifa, IsraelGiuseppe Procopio - Fondazione IRCCS Istituto Nazionale dei TumoriStephen Jay Frank - Hadassah Medical CenterKalevi Pulkkanen - Kuopio University HospitalEli Rosenbaum - Rabin Medical CenterStefano Severi - Istituti di Ricovero e Cura a Carattere ScientificoJose Manuel Trigo Perez - Hospital Universitario Virgen de la Victoria, Málaga, SpainLucia Trandafir - Bayer (Switzerland)Volker Jean Wagner - Bayer (Switzerland)Rui Li - Bayer (United States)Luke T. Nordquist - Urology Cancer Center and GU Research Network
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.5022-5022
- Identifiers
- 991006262309202656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up
Journal of clinical oncology, Vol.36(15_suppl), pp.5022-5022
05/20/2018
Metrics
1 Record Views